Minute Insight: Pulsed AF Trial Of Medtronic’s PulseSelect PFA System Completes Enrollment
PULSED AF is a 500-patient pivotal trial of Medtronic’s PulseSelect PFA system for treating both paroxysmal and persistent atrial fibrillation in patients who have not responded to drugs.
You may also be interested in...
Cardio Catch-Up: Arga, HeartPoint Plan First-In-Human Trials Of Novel Devices; Medtronic And Edwards Announce Product Launches, And More
The second half of summer is usually a slow time for news about cardiac technology innovations because there are not many major conferences. But there was still plenty of innovation news coming from both small and big cardiovascular device companies in July and August.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the first day of the meeting.
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.